文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

按疫苗接种状态监测COVID-19病例、住院和死亡发生率——美国13个辖区,2021年4月4日至7月17日

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-09-17

该研究分析了2021年4月4日至7月17日美国13个辖区≥18岁人群按疫苗接种状态报告的COVID-19病例、住院和死亡。结果显示,未完全接种者与完全接种者的年龄标化发病率比(IRR)在Delta变异株流行前后从11.1降至4.6,住院和死亡IRR分别从13.3降至10.4和从16.6降至11.3,提示疫苗对确诊感染的保护可能下降,但对住院和死亡的保护仍较强。

要点

  • 未完全接种者与完全接种者的病例IRR在Delta变异株流行期从11.1降至4.6。
  • 住院和死亡IRR分别从13.3降至10.4和从16.6降至11.3。
  • 结果提示疫苗对感染的保护可能下降,但对重症的保护仍强。

核心结论

  • 研究结果与疫苗对确诊SARS-CoV-2感染的保护可能下降、但对COVID-19相关住院和死亡的保护仍强相一致。
  • 接种疫苗可预防COVID-19重症(包括Delta变异株),按接种状态监测发病率可提供疫苗保护变化的早期信号。

研究设计与样本

  • 分析2021年4月4日至7月17日美国13个辖区≥18岁人群按疫苗接种状态报告的COVID-19病例、住院和死亡。
  • 13个辖区常规链接病例监测和免疫登记数据。

主要发现

  • 未完全接种者与完全接种者的年龄标化周平均病例IRR在Delta变异株流行率较低期(<50%测序分离株;4月4日-6月19日)为11.1(95%CI=7.8-15.8),较高期(≥50%;6月20日-7月17日)为4.6(95%CI=2.5-8.5)。
  • 住院IRR从13.3(95%CI=11.3-15.6)降至10.4(95%CI=8.1-13.3)。
  • 死亡IRR从16.6(95%CI=13.5-20.4)降至11.3(95%CI=9.1-13.9)。

关键数值与推荐

  • 病例IRR:11.1(95%CI=7.8-15.8)降至4.6(95%CI=2.5-8.5)。
  • 住院IRR:13.3(95%CI=11.3-15.6)降至10.4(95%CI=8.1-13.3)。
  • 死亡IRR:16.6(95%CI=13.5-20.4)降至11.3(95%CI=9.1-13.9)。

临床怎么用

  • 接种疫苗可预防COVID-19重症(包括Delta变异株)。
  • 按疫苗接种状态监测COVID-19发病率可提供疫苗保护变化的早期信号,需通过良好对照的疫苗有效性研究确认。

局限性

  • 研究结果提示疫苗保护变化需通过良好对照的疫苗有效性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccine breakthrough infection surveillance helps monitor trends in disease incidence and severe outcomes in fully vaccinated persons, including the impact of the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19. Reported COVID-19 cases, hospitalizations, and deaths occurring among persons aged ≥18 years during April 4-July 17, 2021, were analyzed by vaccination status across 13 U.S. jurisdictions that routinely linked case surveillance and immunization registry data. Averaged weekly, age-standardized incidence rate ratios (IRRs) for cases among persons who were not fully vaccinated compared with those among fully vaccinated persons decreased from 11.1 (95% confidence interval [CI] = 7.8-15.8) to 4.6 (95% CI = 2.5-8.5) between two periods when prevalence of the Delta variant was lower (<50% of sequenced isolates; April 4-June 19) and higher (≥50%; June 20-July 17), and IRRs for hospitalizations and deaths decreased between the same two periods, from 13.3 (95% CI = 11.3-15.6) to 10.4 (95% CI = 8.1-13.3) and from 16.6 (95% CI = 13.5-20.4) to 11.3 (95% CI = 9.1-13.9). Findings were consistent with a potential decline in vaccine protection against confirmed SARS-CoV-2 infection and continued strong protection against COVID-19-associated hospitalization and death. Getting vaccinated protects against severe illness from COVID-19, including the Delta variant, and monitoring COVID-19 incidence by vaccination status might provide early signals of changes in vaccine-related protection that can be confirmed through well-controlled vaccine effectiveness (VE) studies.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34529637. doi:10.15585/mmwr.mm7037e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。